Two advances signal fast‑moving innovation in cell therapy: a Nature Biotechnology paper described an epigenetic reprogramming platform that enables safe, simultaneous multi‑gene modulation in human T cells without cutting DNA, and a funding report showed Starna Therapeutics raised $44 million to advance in‑vivo CAR‑T programs following early clinical data. The epigenetic method uses CRISPR‑based on/off epigenetic tools to modulate gene expression stably and reversibly, reducing risks tied to permanent genome edits and enabling combinatorial programming of T‑cell traits relevant to persistence and potency. Separately, Starna’s financing will support clinical work on in‑vivo CAR‑T approaches that aim to simplify manufacturing by delivering CAR programs directly to patients. Together, the findings underscore parallel strategies — non‑cutting reprogramming and systemic in‑vivo delivery — to overcome logistic and safety hurdles in cell therapy.